Continuous daily dosing (CDD) study of sunitinib malate (SU) in patients (pts) with advanced GIST compares favorably with intermittent dosing

被引：2

作者：

Blay, J. Y. ^{[1
]}

George, S. ^{[2
]}

Casali, P. G. ^{[3
]}

Le Cesne, A. ^{[4
]}

Morgan, J. A. ^{[2
]}

Pokela, J. ^{[2
]}

Quigley, M. T. ^{[2
]}

Tasse, V. ^{[5
]}

Baum, C. M. ^{[5
]}

Demetri, G. D. ^{[2
]}

机构：

[1] Ctr Leon Berard, F-69373 Lyon, France

[2] Dana Faber Canc Inst, Boston, MA USA

[3] Inst Nazl Tumori, Milan, Italy

[4] Inst Gustave Roussy, Villejuif, France

[5] Pfizer Res & Dev, La Jolla, CA USA

来源：

EJC SUPPLEMENTS | 2007年 / 5卷 / 04期

关键词：

D O I：

10.1016/S1359-6349(07)71478-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7501

引用

页码：402 / 402

页数：1

共 50 条

[1] Continuous daily dosing (CDD) of sunitinib malate (SU) compares favorably with intermittent dosing in pts with advanced GIST
George, S.
Blay, J. Y.
Casali, P. G.
Le Cesne, A.
Morgan, J. A.
Pokela, J.
Quigley, M. T.
Tassell, V.
Baum, C. M.
Demetri, G. D.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[2] Continuous daily dosing (CDD) of sunitinib (SU) in pts with advanced GIST: Updated efficacy, safety, PK and pharmacodynamic analysis
George, S.
Blay, J. Y.
Casali, P. G.
Le Cesne, A.
DePrimo, S. E.
Harmon, C. S.
Law, C. N.
Tassell, V.
Baum, C. M.
Demetri, G. D.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[3] EFFICACY, SAFETY, PHARMACOKINETIC AND PHARMACODYNAMIC ANALYSIS OF SUNITINIB (SU) ADMINSTERED ON A CONTINUOUS DAILY DOSING (CDD) SCHEDULE IN PATIENTS WITH ADVANCED GIST
Blay, J.
George, S.
Casali, P. G.
Le Cesne, A.
Ray-Coquard, I.
Harmon, C. S.
Law, C. N. J.
Tassell, V.
Baum, C. M.
Demetri, G. D.
ANNALS OF ONCOLOGY, 2008, 19 : 267 - 268
[4] Phase II study of sunitinib administered in a continuous daily dosing regimen in patients (pts) with advanced GIST.
George, S.
Casali, P. G.
Blay, J.
Le Cesne, A.
Tyler, A. R.
Quigley, M. T.
Tassell, V.
Baum, C. M.
Demetri, G. D.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 527S - 527S
[5] Clinical benefit of continuous daily dosing of sunitinib in patients (pts) with advanced gastrointestinal stromal tumor (GIST)
Blay, Jean-Yves
George, Suzanne
Casali, Paolo G.
Le Cesne, Axel
Morgan, Jeffrey A.
Tyler, Angela
Quigley, Michael T.
Tassell, Vanessa
Baum, Charles M.
Demetri, George D.
ANNALS OF ONCOLOGY, 2006, 17 : 163 - 163
[6] Clinical activity and tolerability of continuous daily dosing of sunitinib in patients with advanced GIST
Blay, J.
George, S.
Casali, P.
Le Cesne, A.
Morgan, J.
Pokela, J.
Quigley, M.
Tassell, V
Baum, C.
Demetri, G.
ANNALS OF ONCOLOGY, 2007, 18 : VII24 - VII24
[7] Continuous daily dosing of sunitinib in patients with advanced GIST: Initial results of a phase II study
George, S.
Casali, P.
Blay, J.
Le Cesne, A.
Tyler, A.
Quigley, M.
Tassell, V
Baum, C.
Demetri, G.
ANNALS OF ONCOLOGY, 2006, 17 : 28 - 28
[8] Continuous daily dosing (CDD) of sunitinib (SU) in patients with metastatic soft tissue sarcomas (STS) other than GIST: Results of a phase II trial
Keohan, M. L.
Morgan, J. A.
D'Adamo, D. R.
Harmon, D.
Butrynski, J. E.
Wagner, A. J.
Schwartz, G. K.
Maki, R. G.
Demetri, G. D.
George, S.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[9] Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure
George, S.
Blay, J. Y.
Casali, P. G.
Le Cesne, A.
Stephenson, P.
DePrimo, S. E.
Harmon, C. S.
Law, C. N. J.
Morgan, J. A.
Ray-Coquard, I.
Tassell, V.
Cohen, D. P.
Demetri, G. D.
EUROPEAN JOURNAL OF CANCER, 2009, 45 (11) : 1959 - 1968
[10] Continuous or intermittent? On the dosing schedule of sunitinib for advanced renal cell carcinoma
Nozawa, Masahiro
Uemura, Hirotsugu
TRANSLATIONAL ANDROLOGY AND UROLOGY, 2012, 1 (04) : 202 - 203

← 1 2 3 4 5 →